All known patient mutations in the ASH-RhoGAP domains of OCRL affect targeting and APPL1 binding
- 2 May 2008
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 369 (2), 493-499
- https://doi.org/10.1016/j.bbrc.2008.02.067
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Phosphoinositides in cell regulation and membrane dynamicsNature, 2006
- Binding of internalized receptors to the PDZ domain of GIPC/synectin recruits myosin VI to endocytic vesiclesProceedings of the National Academy of Sciences, 2006
- Membrane targeting and activation of the Lowe syndrome protein OCRL1 by rab GTPasesThe EMBO Journal, 2006
- Regulation of phosphoinositide signaling by the inositol polyphosphate 5‐phosphatasesIUBMB Life, 2006
- An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathwayThe Journal of cell biology, 2005
- OCRLMutation analysis in Italian patients with Lowe syndromeHuman Mutation, 2004
- APPL Proteins Link Rab5 to Nuclear Signal Transduction via an Endosomal CompartmentCell, 2004
- Lowe syndrome protein OCRL1 interacts with Rac GTPase in the trans-Golgi networkHuman Molecular Genetics, 2003
- Purification and Identification of Novel Rab Effectors Using Affinity ChromatographyMethods, 2000
- Essential Role of Phosphoinositide Metabolism in Synaptic Vesicle RecyclingCell, 1999